tazemetostat全新购买方式一览

导读：2020年6月18日，美国食品药品管理局加速批准EZH2抑制剂他泽司他（tazemetostat），用于治疗经FDA批准的检测方法检测出肿瘤EZH2突变阳性且先前接受过至少2次全身治疗的复发或难治性滤泡性淋巴瘤成年患者，以及没有满意的替代治疗方案的上皮样肉瘤成年患者。

List of new purchase methods for tazemetostat

You can refer to the following new purchase methods.

1、医院药房：患者可以直接前往tazemetostat上市国家的医院药房购买，这种方式可以获得医生的指导和监督，确保用药安全和正确性。

2. Physical pharmacies: The drug may be sold in local pharmacies in the countries where tazemetostat is listed, and patients can purchase it after presenting a medical prescription.

3.、参与临床试验：在一些情况下，患者可能有机会参与临床试验或患者计划，以获取Tazemetostat，患者需要与研究机构或相关医疗机构联系，了解参与tazemetostat临床试验的条件以及可能的费用或福利。

Please choose the appropriate purchasing channel according to your own situation, and make sure to follow the doctor's advice and local laws and regulations, and understand the side effects, etc.

tazemetostat的不良反应

在 62 例接受tazemetostat800mg每日两次治疗的上皮样肉瘤临床研究中，37%接受 tazemetostat治疗的患者出现严重不良反应。

Serious adverse reactions occurring in ≥3% of patients include bleeding, pleural effusion, skin infection, dyspnea, pain, and respiratory distress. The most common adverse reactions were pain, fatigue, nausea, decreased appetite, vomiting, and constipation.

tazemetostat用药注意事项

继发性恶性肿瘤

接受tazemetostat治疗后，罹患继发性恶性肿瘤的风险会增加。在758名接受 tazemetostat800毫克每日两次单药治疗的成人临床试验中，1.7%的患者患上了骨髓增生异常综合征、急性髓系白血病或B细胞急性淋巴细胞白血病。

Embryo-fetal toxicity

Based on the results of animal studies and its mechanism of action, tazemetostat may cause harm to the fetus when administered to pregnant women. There are currently no data on the use of tazemetostat in pregnant women to inform pregnant women of the risks associated with the drug or to inform pregnant women of possible risks to their fetuses.

It is recommended that women of childbearing potential use effective contraceptive measures during treatment with tazemetostat and for 6 months after the last dose. Advise men with female partners of childbearing potential to use effective contraception during treatment with tazemetostat and for 3 months after the last dose.